Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 5 versus AMINOSYN II 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 5 versus AMINOSYN II 7.
AMINOSYN II 5% vs AMINOSYN II 7%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 5% provides essential and non-essential amino acids for protein synthesis, serving as substrates for nitrogen balance and tissue repair. It supports metabolic processes in patients unable to maintain adequate nutrition enterally.
Aminosyn II 7% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It acts as a substrate for protein synthesis and supports metabolic functions in patients unable to tolerate oral or enteral nutrition.
Intravenous infusion via central line, initial rate 50 mL/hour, increase by 25 mL/hour every 24 hours to goal rate of 1-2 mL/kg/hour (maximum 125 mL/hour). Total daily dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 30-40 mL/kg/day).
Intravenous infusion; typical adult dose: 0.8-1.5 g amino acids/kg/day (11.4-21.4 mL/kg/day of 7% solution); rate not exceeding 0.1 g amino acids/kg/hour.
None Documented
None Documented
Not applicable as a single entity; individual amino acids have variable half-lives (e.g., 10-30 min for most), reflecting rapid distribution and metabolism. Clinical context: continuous infusion maintains steady state.
Not applicable; exogenous amino acids are rapidly cleared from plasma with a terminal half-life of 15-20 minutes for individual amino acids.
Renal elimination of amino acids is minimal under normal conditions; excess amino acids are metabolized, and nitrogen is excreted as urea (renal, ~80-90%) and ammonia. Biliary/fecal excretion negligible.
Renal as amino acids and metabolites; negligible biliary/fecal.
Category C
Category C
Amino Acid Solution
Amino Acid Solution